Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfunction and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in diabetic apolipoprotein E-deficient

被引：0
|
作者：
Ganbaatar, B. [1 ]
Fukuda, D. [2 ]
Yagi, S. [1 ]
Kusunose, K. [1 ]
Yamada, H. [1 ]
Soeki, T. [1 ]
Sata, M. [1 ]
机构：
[1] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Cardiovasc Med, Tokushima, Japan
[2] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Cardiodiabet Med, Tokushima, Japan
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3111
引用
收藏
页码：1881 / 1881
页数：1
相关论文
共 17 条
  • [1] Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
    Ganbaatar, Byambasuren
    Fukuda, Daiju
    Shinohara, Masakazu
    Yagi, Shusuke
    Kusunose, Kenya
    Yamada, Hirotsugu
    Soeki, Takeshi
    Hirata, Ken-ichi
    Sata, Masataka
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 875
  • [2] Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
    Rahadian, A.
    Fukuda, D.
    Salim, H.
    Yagi, S.
    Kusunose, K.
    Yamada, H.
    Soeki, T.
    Sata, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 329 - 329
  • [3] Resveratrol improves endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice
    Li, Jinghua
    Zhong, Zhenwei
    Yuan, Jiru
    Chen, Xiaohang
    Huang, Ziyang
    Wu, Zeyu
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2019, 67 : 63 - 71
  • [4] Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice
    Aini, Kunduziayi
    Fukuda, Daiju
    Tanaka, Kimie
    Higashikuni, Yasutomi
    Hirata, Yoichiro
    Yagi, Shusuke
    Kusunose, Kenya
    Yamada, Hirotsugu
    Soeki, Takeshi
    Sata, Masataka
    INTERNATIONAL HEART JOURNAL, 2019, 60 (06) : 1421 - 1429
  • [5] N-methylnicotinamide protects against endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice
    Jiang, Nan
    Wang, Min
    Song, Jiayi
    Liu, Yan
    Chen, Hongen
    Mu, Di
    Xia, Min
    MOLECULAR NUTRITION & FOOD RESEARCH, 2016, 60 (07) : 1625 - 1636
  • [6] Benefits of the Sglt2 Inhibitor Empagliflozin on Epicardial Adipose Tissue in Non-Diabetic Hfref
    Santosgallego, Carlos G.
    Requena-Ibanez, Juan Antonio
    Botija, Maria Belen Picatoste
    Ishikawa, Kiyotake
    Sanz, Javier
    Fuster, Valentin
    Badimon, Juan J.
    CIRCULATION, 2022, 146
  • [7] Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice
    Ganbaatar, Byambasuren
    Fukuda, Daiju
    Shinohara, Masakazu
    Yagi, Shusuke
    Kusunose, Kenya
    Yamada, Hirotsugu
    Soeki, Takeshi
    Hirata, Ken-Ichi
    Sata, Masataka
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2021, 28 (06) : 630 - 642
  • [8] Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis Independent of Its Glucose Lowering Effect in Apolipoprotein E-deficient Mice
    Kunduziayi, Aini
    Fukuda, Daiju
    Yagi, Shusuke
    Kusunose, Kenya
    Hirotsugu, Yamada
    Soeki, Takeshi
    Sata, Masataka
    CIRCULATION, 2019, 140
  • [9] SGLT2 Inhibitor Attenuates Inflammatory Response in Diabetic Kidney Disease by Inhibiting GSDMD-Related Pyroptosis
    Ren, Shijing
    Xue, Yaoming
    DIABETES, 2020, 69
  • [10] The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats
    Aragon-Herrera, Alana
    Morana-Fernandez, Sandra
    Otero-Santiago, Manuel
    Anido-Varela, Laura
    Campos-Toimil, Manuel
    Garcia-Seara, Javier
    Roman, Ana
    Seijas, Jose
    Garcia-Caballero, Lucia
    Rodriguez, Javier
    Tarazon, Estefania
    Rosello-Llei, Esther
    Portoles, Manuel
    Lage, Ricardo
    Gualillo, Oreste
    Gonzalez-juanatey, Jose Ramon
    Feijoo-Bandin, Sandra
    Lago, Francisca
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
12